Delving into the Latest Updates on 美亞製藥廠有限公司 with Synapse

概览

关联

1

项与美亞製藥廠有限公司相关的临床试验

NCT00003780 / Unknown status临床2期

An Open Label Randomized Trial Comparing the Safety and Efficacy of Systemic Chemotherapy (Gemcitabine) to Immunotherapy (CYTOIMPLANT - Intra Tumor Implants of Allogeneic Peripheral Blood Mononuclear Cells Sensitized Against Patient Alloantigens by Mixed Lymphocyte Culture) as First Line Therapy for Patients With Unresectable Locally Advanced, and Metastatic Pancreatic Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known whether chemotherapy is more effective than biological therapy in treating patients with cancer of the pancreas.
PURPOSE: Randomized phase II trial to compare the effectiveness of gemcitabine with biological therapy in treating patients who have cancer of the pancreas that cannot be surgically removed.

开始日期1998-12-01

申办/合作机构

美亞製藥廠有限公司

100 项与美亞製藥廠有限公司相关的临床结果

登录后查看更多信息

0 项与美亞製藥廠有限公司相关的专利（医药）

登录后查看更多信息

100 项与美亞製藥廠有限公司相关的药物交易

登录后查看更多信息

100 项与美亞製藥廠有限公司相关的转化医学

登录后查看更多信息